Clinical Trials

CLEAR SYNERGY is an international multi center 2x2 randomized placebo-controlled trial of colchicine and spironolactone in patients with STEMI.

Do you have coronary heart disease, and are you interested in helping researchers improve how they treat and prevent this condition? This study is exploring new risk factors that may allow for more people with heart disease to get approved for an implantable cardioverter defibrillator (ICD), a device that can detect and stop irregular heartbeats. To participate in this study, you must be 18 years old or older and already have or be eligible for an ICD. This study takes place in Buffalo, New York.

In this study, the investigators will recruit a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests.

The purpose of this study is to test whether an over-the-counter ketone ester drink is well tolerated in people with heart failure on, and not on, a heart failure medication class called SGLT2 inhibitors. The research team is trying to determine the safest dose of Delta G.

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Are you a professional caregiver for an adult who has serious heart failure? This study is testing whether electronic educational resources, in addition to in-person training , help home aids be more knowledgeable and confident in caring for adults who have serious heart failure. To participate in this study, you must be between 18 and 75 years old, be employed at Visiting Nurse Service of New York's Partners in Care agency, and care for an adult who has heart failure. This study is located in New York, New York.

Are you an adult with ischemic cardiomyopathy? This study is investigating ways to prevent sudden cardiac arrest in people with ischemic cardiomyopathy. Researchers in this study are also working to determine which patients could benefit from an implantable cardioverter defibrillator, a device that is connected to the heart that can detect and stop irregular heartbeats called arrythmias. To participate in this study, you must be 18 years old or older and have ischemic cardiomyopathy. This study takes place in Buffalo, New York.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.